The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2023 / Nov / QTOF: Quick Off the Mark for Oligonucleotide Analysis
Pharma and Biopharma Mass Spectrometry News and Research Technology

QTOF: Quick Off the Mark for Oligonucleotide Analysis

Experts from Axolabs GmbH and Bruker Daltonics explain the benefits behind mass spectrometry for oligonucleotides in drug discovery

By Stephan Seiffert, Julia Schneider, Christian Albers, Timo Schierling 11/15/2023 4 min read
  • Full Article
  • Summary
  • Takeaways

Share

5 Key Takeaways
  • 1

    Oligonucleotides are synthetic DNA or RNA strands used in biotechnology, diagnostics, forensics, and pharmaceuticals.

  • 2

    Antisense oligonucleotides (ASOs) target mRNA to modulate gene expression, particularly for neurodegenerative diseases.

  • 3

    Accurate analysis of oligonucleotides is essential for regulatory approval, impacting drug safety and efficacy.

  • 4

    QTOF MS instruments provide high mass accuracy and sensitivity for characterizing complex oligonucleotide sequences.

  • 5

    Recent software advancements enhance QTOF MS data interpretation, facilitating faster and more accurate oligonucleotide analysis.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Bruker Daltonics, Bruker Announces Makor Advances in CCS-Enabled 4D Proteomics at ASMS, 2021, https://www.businesswire.com/news/home/20211102005437/en/Bruker-Announces-Major-Advances-in-CCS-Enabled-4D-Proteomics-at-ASMS
  2. Damase T.R, The Limitless Future of RNA Therapeutics, Frontiers in Bioengineering and Biotechnology, 2021, https://www.frontiersin.org/articles/10.3389/fbioe.2021.628137/full
  3. Roberts T.C, Advances in oligonucleotide drug delivery, Nature Reviews Drug Discovery, 2020, https://www.nature.com/articles/s41573-020-0075-7
  4. Sutton, J.M, et al, Current State of Oligonucleotide Characterization Using Liquid Chromatography-Mass Spectrometry: Insight into Critical Issues, 2020, https://pubs.acs.org/doi/pdf/10.1021/jasms.0c00179#
  5. Anjali Alving, Bruker Daltonics, Simplifying Oligonucleotide Drug Development Workflows with Mass Spectrometry, 2019, https://www.bruker.com/en/news-and-events/webinars/2019/simplifying-oligonucleotide-drug-development-workflows-with-mass-spectrometry.html

About the Author(s)

Stephan Seiffert

Stephan Seiffert studied Chemistry in Regensburg, Germany, and joined Alnylam Europe 2004 as a scientist in the Analytics group. He is now team leader at Axolabs, responsible for 12 employees, in non-regulated analytics. He has more than 18 years extensive experience with high-performance liquid chromatography (HPLC) and mass spectrometry (MS), as well as various techniques that support the characterization of oligonucleotides, including mRNA.

More Articles by Stephan Seiffert

Julia Schneider

Principal Research Associate

More Articles by Julia Schneider

Christian Albers

Business Development Manager, Pharmaceuticals Market, Bruker Daltonics

More Articles by Christian Albers

Timo Schierling

Scientist (Analytics R&D)

More Articles by Timo Schierling

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.